SERA (Sera Prognostics, Inc. Class A Common Stock) Stock | Pipeline, Insider Trades & Financials

Jul 29, 2026

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

Sera Prognostics Inc. will report its second quarter fiscal year 2026 financial results on August 12, 2026. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and operational highlights. The company aims to enhance maternal and neonatal health through innovative biomarker information.

Jul 9, 2026

PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE

Sera Prognostics announced a subgroup analysis from the PRIME trial showing that PreTRM Test-guided care significantly reduces NICU admissions by 22% in first-time pregnancies. The study highlights the test's ability to improve neonatal outcomes and suggests substantial healthcare savings. This innovative approach offers early risk identification, enabling timely interventions for better maternal and neonatal health.

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS

Sera Prognostics has appointed Mark Capone to its Board of Directors, effective July 1, 2026. Capone brings over 40 years of experience in healthcare, particularly in diagnostics and life sciences, including his role as CEO of Myriad Genetics. His expertise is expected to support Sera's growth and the adoption of its PreTRM test, which predicts preterm birth risk.

Jun 24, 2026

SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH

Sera Prognostics is collaborating with UC San Diego and Allegro MicroSystems on a $10.4 million ARPA-H grant to develop a point-of-care diagnostic test for fetal hypoxia. This initiative aims to enhance decision-making during childbirth by providing timely information from maternal blood samples. The project reflects a shift towards proactive maternal health management.

Jun 23, 2026

SERAFDA Updates

SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY

Sera Prognostics has praised Illinois for its new legislation that expands Medicaid coverage for proteomic blood testing aimed at identifying and managing preterm birth risks. This initiative is expected to enhance maternal and neonatal health outcomes by providing early risk assessment tools. The PreTRM Test, developed by Sera, is highlighted as a key component in this effort.

Jun 1, 2026

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

Sera Prognostics announced that Jeff Elliott will step down from its Board of Directors effective June 4, 2026. Elliott, who has been with the board since March 2025, cited increasing demands on his time as the reason for his departure. The company is actively seeking new board members to ensure leadership continuity.

Jun 1, 2026

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION Salt Lake City &#x2013

Sera Prognostics announced that board member Jeff Elliott will step down effective June 4, 2026, due to time constraints. Elliott, who joined the board in March 2025, has contributed to the company's strategic direction during its growth phase. The company is actively seeking qualified candidates to fill the board position. Sera Prognostics focuses on precision pregnancy care to improve health outcomes for mothers and newborns.

May 6, 2026

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics reported its financial results for Q1 2026, highlighting a focus on commercial readiness and clinician engagement. The company published significant findings from the PRIME trial, showing its PreTRM test's effectiveness in reducing preterm births. Despite a decrease in revenue and a slight increase in net loss, Sera is actively expanding its partnerships and preparing for regulatory submissions in Europe.

Apr 22, 2026

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

Sera Prognostics Inc. has announced a conference call and webcast scheduled for May 6, 2026, to discuss its first quarter fiscal year 2026 financial results. The call will include operational highlights and a press release will be issued prior to the event. The company focuses on innovative pregnancy biomarker information to enhance maternal and neonatal health.

Mar 18, 2026

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2025 FINANCIAL RESULTS Salt Lake City &#x2013

Sera Prognostics Inc. has reported its financial results for the fourth quarter and full year 2025, highlighting several significant developments. The positive outcomes from the PRIME Study on the PreTRM Test suggest a substantial impact on reducing preterm births and complications. The company has also expanded its commercial efforts and solidified its leadership team. However, despite these achievements, Sera continues to face financial losses and declining revenue in the last quarter of 2025.

Mar 4, 2026

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

Sera Prognostics Inc. will report its fourth quarter and fiscal year 2025 financial results on March 18, 2026. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and operational highlights. The company aims to improve maternal and neonatal health through innovative pregnancy biomarker information.

Feb 17, 2026

SERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE

Sera Prognostics Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. The presentation will include a fireside chat discussing the company's latest achievements. Sera Prognostics aims to enhance maternal and neonatal health through its PreTRM Test, which predicts the risk of preterm birth.

Jan 8, 2026

▲ +7%on this news

JANUARY 2026 We are redefining pregnancy care to reduce the burden of preterm birth This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than state

Sera is aiming to redefine pregnancy care by introducing the PreTRM test, a blood-based predictor of spontaneous preterm birth risk. This test is clinically validated and supported by multiple studies. The company highlights an urgent need to address the economic burden of preterm births, which have been increasing in recent years. However, the company also acknowledges the substantial risks and uncertainties involved in their forward-looking statements regarding future operations and expectations.

Jan 7, 2026

▲ +11.5%on this newsshared move

Landmark Study Finds PreTRM Blood Test Reduces Earliest Preterm Births and Newborn Complications Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early r

The PRIME Study, recently published in the journal PREGNANCY, reveals that the PreTRM blood test significantly reduces preterm births and associated complications. Involving a randomized controlled trial of 5,018 women, the study demonstrated a 56% and 32% reduction in births before 32 and 35 weeks, respectively, along with a decrease in NICU admissions. The test's effectiveness lies in its ability to identify higher-risk women for preterm birth, allowing for targeted interventions. The findings highlight the potential for transforming maternal and neonatal care and improving health outcomes, especially for disadvantaged populations.

Nov 24, 2025

Sera Announces Publication Acceptance for PRIME Study The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year

Sera Prognostics, Inc. has announced that the findings of its PRIME study, one of the largest studies focused on preterm birth, have been accepted for publication in a peer-reviewed journal. Earlier this year, the study's abstract was presented at the Society for Maternal-Fetal Medicine's annual meeting. The acceptance signifies a substantial step in the company's mission to enhance maternal and neonatal health through precise pregnancy care. Sera Prognostics aims to share detailed manuscript data at upcoming medical meetings for further scholarly communication.

SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS Salt Lake City &#x2013

Sera Prognostics, Inc. reported its third quarter 2025 financial results, highlighting progress in payer initiatives and a Medicaid pilot program in Nevada. The company is preparing to publish full results from its pivotal PRIME study, which may lead to improved adoption of its PreTRM Test. Despite a revenue drop compared to the previous year and a net loss of $7.8 million, Sera's leadership changes and market engagement show potential for future growth. Their efforts continue to focus on enhancing maternal and neonatal health through innovative diagnostic solutions.

Sep 5, 2025

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements rega

Sera seeks to redefine pregnancy care by developing predictive diagnostics to address the issue of preterm birth. With a strong cash position extending to 2028, the company aims to advance the commercialization of its PreTRM test, which is uniquely validated for early prediction of premature birth. Sera is focused on empowering healthcare providers and patients with better information to improve maternal and neonatal health outcomes. As preterm birth rates continue to rise, Sera's initiatives may play a critical role in addressing this growing concern.

SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Salt Lake City &#x2013

Sera Prognostics Inc. reported its financial results for Q2 2025, showing a revenue decrease from $24,000 to $17,000 and an operating expense of $9.3 million. Notably, the company is making strides in engaging Medicaid plans in key states and is on track to publish results of its PRIME study. Sera has recently strengthened its leadership team with several appointments aimed at boosting its commercial efforts. The company holds $108.5 million in cash reserves to support its operations and anticipated growth through 2028.

SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company Salt Lake City &#x2013

Sera Prognostics Inc. has appointed Lee Anderson as Chief Commercial Officer to lead its commercial expansion. With over 30 years of experience in sales and marketing within the healthcare sector, Anderson is expected to drive growth for the company's PreTRM Test, which predicts preterm birth risk. His prior roles include executive positions at Genomic Health and Exact Sciences, contributing to significant revenue growth. The company is focused on enhancing maternal and neonatal health through innovative diagnostic solutions.

May 7, 2025

SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Salt Lake City &#x2013

Sera Prognostics Inc. has reported financial results for the first quarter of 2025, highlighting a revenue of $38,000 as compared to nil for the same period in 2024. The company is actively pursuing Medicaid opportunities and engaging with payors to enhance access to its PreTRM Test, following positive outcomes from the PRIME study. Despite an increase in revenue, Sera faced an $8.2 million net loss, indicating continued financial challenges. Upcoming plans include a strong presence at the ACOG 2025 meeting to further promote its offerings.

Mar 19, 2025

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS Salt Lake City &#x2013

Sera Prognostics Inc. announced its financial results for the fourth quarter and full year of 2024, reporting a revenue decline but significant advancements in its PRIME study. The PRIME study showed positive outcomes, including a 25% reduction in neonatal morbidity and an 18% reduction in hospital stays. The company successfully raised $57.5 million in February 2025 to support its operations and expansion plans while aiming to increase the adoption of its PreTRM test in the U.S. and Europe. Despite a net loss of $8.6 million for the quarter, Sera is optimistic about its future growth trajectory.

Feb 10, 2025

Sera Prognostics Announces Proposed Public Offering Salt Lake City

Sera Prognostics, Inc. has announced a proposed public offering of its Class A common stock, aiming to enhance its operational capabilities and explore expansion opportunities. The company plans to utilize the proceeds for various initiatives, including studies to promote its PreTRM test and to pursue broader FDA approval. This offering remains contingent on market conditions and may not materialize as planned. The involvement of prominent underwriters suggests confidence in the company’s growth potential, though there are inherent risks associated with market acceptance and financial stability.

Jan 31, 2025

WE AT SERA AIM TO CHANGE PREGNANCY CARE } In order to transform the experience into one with fewer uncertainties 2025 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or

Sera Prognostics, Inc. is working towards revolutionizing pregnancy care by reducing uncertainties associated with preterm birth through its PreTRM Test. This test uses a single blood draw performed between weeks 18-20 of gestation to accurately predict spontaneous preterm birth risk, leveraging advanced proteomics technology. Enhanced screening practices are essential, given the significant clinical challenges posed by preterm births, which affect neonatal morbidity and mortality rates. The company's innovative approach positions it at the forefront of prenatal diagnostics and healthcare improvement.

Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. In order to transform the experience into one w

Sera Prognostics, Inc. has released its Q3 2024 earnings report, highlighting a strong cash position of approximately $75 million, which is projected to support its operations well into 2027. The report indicates that the company's annual operating expenses are under $30 million, enabling continued focus on commercialization efforts. This financial stability positions Sera strategically as it aims to achieve a significant revenue inflection point in the near future.

SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Salt Lake City &#x2013

Sera Prognostics Inc. reported its financial results for the third quarter of 2024, revealing revenues of $29,000 and a net loss of $7.9 million. The company is actively working on the publication of results from its PRIME study and has launched an awareness campaign to broaden the reach of its PreTRM testing. Notably, they are transitioning to ambient whole blood collection to enhance scalability and lower costs. Despite a decrease in revenue compared to the prior year, the management is optimistic about future growth driven by consumer-initiated testing and the anticipated study results.

Aug 7, 2024

SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Salt Lake City

Sera Prognostics Inc. reported its financial results for Q2 2024, highlighting a revenue drop to $24,000 from $123,000 in the same period last year. Despite this decline, the company published positive results of the AVERT PRETERM TRIAL in a peer-reviewed journal and received conditional approval for a new blood collection method. The company's cost-cutting measures have narrowed net losses, which are now at $8.3 million, down from $10.5 million a year ago. Future growth may rely on the upcoming PRIME study publication and ongoing educational initiatives for the PreTRM Test.

May 8, 2024

SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Salt Lake City

Sera Prognostics Inc. reported its financial results for Q1 2024, revealing a revenue of $39,000 before adjustments, a decline from $100,000 in Q1 2023. The company is taking steps to improve cost efficiencies and explore international market opportunities, particularly for its PreTRM Test. Although operating expenses decreased significantly, the net revenue was nil due to accounting adjustments. The company remains focused on enhancing its evidence portfolio to promote wider adoption of its technology.

Mar 20, 2024

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS Salt Lake City

Sera Prognostics Inc. announced its fourth quarter and full year 2023 financial results, highlighting a decrease in revenue but a notable reduction in operating expenses. The company received a recommendation from the Data Safety Monitoring Board to stop enrollment in its PRIME study due to meeting efficacy endpoints. Sera is advancing its product pipeline and plans to improve PreTRM test adoption while focusing on developing relationships with expectant mothers. Despite a net loss, Sera's leadership maintains a positive outlook for upcoming developments and revenue growth in 2024 and beyond.

Dec 6, 2023

▲ +161.4%on this news

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK

Sera Prognostics announced that its pivotal PRIME study has met the primary endpoint criteria during an interim look, leading to a recommendation from the Data Safety Monitoring Board to stop enrollment due to efficacy. The company will now focus on analyzing the gathered data for insights. This early achievement is viewed positively within the company as it aligns with their mission to enhance maternal and neonatal health through innovative diagnostics, particularly their PreTRM test for predicting preterm birth risk.

Nov 8, 2023

SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Salt Lake City

Sera Prognostics Inc. reported its financial results for Q3 2023, revealing a significant decline in revenue from $87,000 to $42,000 while reducing operating expenses from $11.3 million to $8.2 million. The company has made strategic appointments to its leadership and completed cost-reduction initiatives to extend its cash runway. They are focusing on enhancing their care coordination offerings and have advanced their new risk prediction product into market research. Additionally, findings from a clinical trial highlight the efficacy of their PreTRM test in improving neonatal outcomes.

Sep 25, 2023

Sera Prognostics has announced a collaboration with Elevance to improve maternal and neonatal health through the PreTRM identification method. This collaboration involves a multicenter prospective randomized controlled study with up to 6,500 participants across approximately 15 U.S. sites. The primary outcomes will focus on reducing hospital lengths of stay and neonatal morbidity and mortality, creating valuable data for future clinical applications of PreTRM.

Aug 9, 2023

SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Salt Lake City

Sera Prognostics Inc. reported its second-quarter 2023 financial results, revealing a rise in revenue to $123,000 compared to $78,000 a year earlier. The company announced recent leadership changes aimed at optimizing commercial strategy and enhancing revenue for its PreTRM Test. Despite these positive developments, the net loss remains significant at $10.5 million, though this has improved from the previous year's loss. The company also made headcount reductions to align costs, which reflects challenges in the current market environment.

Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue Aligning Management Team given New Refined Commercial Focus on Institutions

Sera Prognostics has announced commercial changes aimed at optimizing its business strategy to enhance test adoption and revenue, focusing on institutions. The company has appointed Zhenya Lindgardt as interim President and CEO while engaging a leading strategy firm to explore effective revenue pathways. Additionally, Nadia Altomare is transitioning to a consulting role to improve efficiency, and the company has implemented headcount reductions to better align costs with new strategies. These actions are part of a broader effort to position the PreTRM Test as a market standard amidst challenges in achieving broad acceptance.

May 15, 2023

Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim

Sera Prognostics announced the retirement of Dr. Greg Critchfield, President and CEO, effective June 8, 2023, after 12 years of service. Zhenya Lindgardt, a board member, has been appointed as Interim CEO. The board expressed gratitude for Critchfield's leadership in advancing the company's initiatives, particularly the PreTRM test for predicting preterm birth risk. Lindgardt's experience is expected to guide the company's strategy moving forward, leveraging a robust pipeline of pregnancy-related diagnostic solutions.

May 10, 2023

SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Salt Lake City

Sera Prognostics announced its financial results for the first quarter of 2023, highlighting positive developments such as increased physician orders for its PreTRM test and successful interim data from its AVERT PRETERM TRIAL. The company's revenue reached $100,000, a substantial increase from the previous year, while operating expenses decreased. Despite an overall net loss of $10.6 million, Sera maintains a significant cash position of approximately $100 million. The company plans to submit new data for scientific review this summer, aiming to enhance market presence and acceptance.

Mar 22, 2023

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS Salt Lake City

Sera Prognostics reported its fourth quarter and full year 2022 financial results, highlighting a positive trend in revenue due to effective clinical testing strategies. The AVERT PRETERM TRIAL showcased successful outcomes, validating their PreTRM test. Despite revenue growth, the company reported a net loss and rising operating costs, reflecting ongoing financial challenges as it expands its portfolio of pregnancy-related diagnostic tools. The publication of significant studies further supports Sera's mission to enhance maternal and neonatal health.

Nov 9, 2022

SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Salt Lake City

SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Salt Lake City - November 9, 2022 - Sera Prognostics Inc., The Pregnancy Company (Nasdaq SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and

SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Salt Lake City

SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Salt Lake City - August 10, 2022 - Sera Prognostics Inc., The Pregnancy Company (Nasdaq SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and

May 10, 2022

SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Salt Lake City

SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Salt Lake City - May 10, 2022 - Sera Prognostics Inc., The Pregnancy Company (Nasdaq SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and pati

Apr 12, 2022

▼ -11.3%on this news· ran to -23% by day 3

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies

"I am excited to join Sera's board and its focus on meaningful and innovative solutions to improve the well being of mothers and newborns," said Dr. Jane Barlow. "Sera's personalized approach to advancing the health of pregnant mothers and babies is an enabler of improved outcome

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS Salt Lake City

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS Salt Lake City - March 29, 2022 - Sera Prognostics Inc., The Pregnancy Company (Nasdaq SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and p

Nov 30, 2021

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF SANDRA A.J. LAWRENCE TO THE SERA PROGNOSTICS BOARD Highly respected healthcare and financial leader joins Sera in its quest to improve pregnancy outcomes of mothers and babie

where she serves as chair of the Audit Committee and as a member of the Nominating and Corporate Governance Committee. Additionally, she serves on the board, as chair of the Risk Oversight Committee, and on the Governance, Compliance, and Talent and Compensation Committees, of Re

Nov 9, 2021

SERA PROGNOSTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS Salt Lake City

SERA PROGNOSTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS Salt Lake City - November 9, 2021 - Sera Prognostics Inc., The Pregnancy Company (Nasdaq SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and

Nov 8, 2021

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF ZHENYA LINDGARDT TO THE BOARD Noted healthcare and technology executive joins to help Sera achieve its vision as The Pregnancy Company to improve maternal and newborn health

About Sera Prognostics, Inc. Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to deliver early, pivotal information in pregnancy to physicians, enabling them to improv

Aug 30, 2021